

Application of Nazarov cyclization to access [6-5-6] and [6-5-5]tricyclic core embedded new heterocycles: an easy entry to structures related to Taiwaniaquinoids†

Ritesh Singh, Maloy Kumar Parai and Gautam Panda*

Received 26th January 2009, Accepted 3rd March 2009

First published as an Advance Article on the web 27th March 2009

DOI: 10.1039/b901632e

A concise and general route to synthesize a new class of [6-5-6] tricyclic core embedded polyheterocycles has been accomplished using diastereoselective Nazarov cyclization with an overall yield of 35–40%. Versatility of this synthetic route has also been demonstrated by accessing a variety of [6-5-5] tricyclic core incorporated polycycles. It was observed that the efficiency of cyclization depends upon the impact of polarization on the reacting systems. Amongst the various Lewis and Brønsted acids screened for cyclization, triflic acid was found to be the most effective catalyst.

Introduction

The [6-5-6]ABC tricyclic skeleton, which is rather uncommon, has been found in several natural products, among which the taiwaniaquinoids deserve a special mention (Fig 1).^{1a-c} Taiwaniaquinol B, isolated from Taiwanese pine tree *Taiwania cryptomerioides*, is one such 6-nor-5(6→7)abeo-abietane type diterpenoid containing the uncommon fused [6-5-6] tricyclic carbon skeleton.² Several members of the taiwaniaquinoids have shown activity as aromatase inhibitors and are currently under evaluation for their potential as drug leads in the treatment of estrogen-dependent cancers.^{3,4} Thus, the distinctive [6-5-6] fused ring system has received considerable attention from synthetic organic chemists, and several total syntheses of such norditerpenoids have appeared in the last few years.⁵





Fig. 1 Representative natural [6-5-6] tricyclic skeleton and our designed novel [6-5-6]/[6-5-5] skeleton embedded polycycles.

Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow-226001, UP, India. E-mail: gautam.panda@gmail.com, gautam_panda@cdri.res.in; Fax: 91-522-2623405; Tel: 91-522-2612411-18

† Electronic supplementary information (ESI) available: ¹H and ¹³C NMR spectra of compounds **9**, **10**, **13**, **14**, **15**, **16**, **19**, **20**, **21**, ¹H-¹H COSY, HSQC, HMBC spectra of **15k** and scheme for synthesis of **16**. See DOI: 10.1039/b901632e

The Nazarov reaction⁶ is considered as one of the most versatile reactions to construct cyclopentenone fused carbocycles. Although the concept of the polarized Nazarov substrate,⁷ *i.e.* divinyl ketone **1**, has been exploited to construct simple functionalized cyclopentenone **3** *via* intermediate **2** under mild reaction conditions (Scheme 1), its utilization for the construction of [6-5-6] tricyclic skeleton fused heteropolycycles is rather limited.⁸ Trauner *et al.* utilized the Nazarov chemistry efficiently to synthesize several members of the Taiwaniaquinoid family containing [6-5-6] tricyclic skeleton including Taiwaniaquinol B using trimethylsilyl triflate (TMSOTf) in nitromethane.⁹ Fillion *et al.* reported the synthesis of Taiwaniaquinol B, applying domino acylation/alkylation as a key step.^{5a} Approaches based on palladium catalyzed alkylation^{5b} and intramolecular Heck reactions^{5c-e} to assemble [6-5-6] tricyclic skeleton containing natural products have also been well delineated by several groups. However, as such, no general and efficient method to assemble heterocycles with heteroatom impregnated [6-5-6] tricyclic skeleton has been reported so far.




Scheme 1 A general polarized Nazarov reaction and our designed polarized substrate **4**.

Therefore, a mild and expedient method for the construction of heteroatom embedded [6-5-6] tricyclic skeletons is highly desirable.

In the quest for attaining novel molecules with interesting properties, we envisaged to encompass the polarized Nazarov concept to access diversified [6-5-6] tricyclic skeletons. Further cognizing the fact that the *cis* ring fusion preferences in the cyclic systems could direct the protonation in diastereoselective Nazarov product,^{10,11} we endeavoured to design a new class of polarized Nazarov substrate **4** by casting aromatics/heteroaromatics¹² as vinyl nucleophiles to access a variety of novel benzene annulated [6-5-6]/[6-5-5] tricyclic heteropolycycles **6** via intermediate **5**.

Results and discussion

The general retrosynthetic analysis of the target molecule depicted that the Nazarov substrates **D** could be assembled by oxidizing the alcohol **C**, which would be procured through the coupling of suitable bromo substrates **A** with different aromatic and heteroaromatic aldehydes **B** (Scheme 2).



Scheme 2 Retrosynthetic analysis of target molecule.

Towards the realization of our goal, we first embarked upon the syntheses of benzo annulated [6-5-6]tricyclic skeleton embedded polyheterocycles. Syntheses of the Nazarov substrates **10a-c** were achieved as outlined in Scheme 2. Chromanones/thiochromanones **7** were treated with PBr_3 in dry benzene at 60°C to furnish the bromo compounds **8a-c** in good yields (60–64%).¹³ **8a-c** were further treated with *n*-BuLi under an inert atmosphere at -78°C in dry THF and reacted with commercially available veratraldehyde **11** to obtain the corresponding divinyl alcohols **9a-c** in reasonable yields (55–60%). MnO_2 oxidation of allylic alcohols **9a-c** furnished the coveted Nazarov substrate **10a-c** in high yields (80–85%).

In an effort to optimize the best catalyst for the Nazarov cyclization to obtain the [6-5-6] tricyclic core of **12a-c**, substrates **10a-c** were reacted with various catalytic Lewis and Brønsted acids in dichloromethane at room temperature (Table 1). It was observed that the Nazarov substrates **10a-c** cyclized to furnish the [6-5-6] tricyclic embedded heteropolycycles **12a-c** in high yields (87–91%) at room temperature with just one equivalent of triflic acid in a very short reaction time. Besides triflic acid, other Brønsted acids such as H_2SO_4 , CF_3COOH and *p*-TsOH also gave the cyclized product albeit in low yields (65–85%) and longer reaction times. Well known Lewis acids like AlCl_3 , FeCl_3 , $\text{BF}_3\cdot\text{Et}_2\text{O}$ did not show

Table 1 Catalyst optimization for Nazarov cyclization

Entry	Substrate	Catalyst	Conditions	Time/h	Yield
1	10a	$\text{CF}_3\text{SO}_3\text{H}$	DCM, rt	1.5	91%
2	10a	H_2SO_4	DCM, rt	3	85%
3	10c	CF_3COOH	DCM, rt	2.5	82%
4	10b	<i>p</i> -TsOH	DCM, rt	12	65%
5	10b	AlCl_3	DCM, rt	10	62%
6	10c	FeCl_3	DCM, rt	16	45%
7	10a	$\text{BF}_3\cdot\text{Et}_2\text{O}$	DCM, rt	14	47%
8	10c	$\text{Sc}(\text{OTf})_3$	DCM, rt	48	28%

very good reactivity and remained low yielding even after an increase in the catalyst loading (47–62%).

Use of milder Lewis acid like $\text{Sc}(\text{OTf})_3$ also did not improve the reactivity significantly, as a substantial amount of substrate was left unreacted even after 48 hrs (28% yield) (Table 1). The *syn* stereochemistry established by NOESY experiments in the products **12a-c** reflects the greater stability of *cis* fused cyclopentenone [6-5-6] tricyclic systems. This is due to the enol protonation step of one of the intermediates **c** in the Nazarov cyclization process (Scheme 4) during the aqueous workup, which gave thermodynamically favourable *cis* fused products. However, it was delightful to achieve products with excellent diastereoselectivity (>99%) with no trace of other isomer detected even in the HPLC analysis. Change of solvent from DCM to dry benzene did not change the yields. With the best optimized reaction conditions at hand, we set out to explore the generality of the synthetic pathway to synthesize new molecular entities embedded with [6-5-6] tricyclic systems. Thus **14a** (eq 1) and **21** (eq 3) were synthesized (Scheme 5) from bromo substrates **8b** and **22**¹⁴ with benzaldehyde and veratraldehyde respectively, following similar reaction conditions as given in Scheme 3. But to our dismay, **14a** failed to give the cyclized product under the optimized cyclization reaction conditions indicating that activated aromatic rings are required for cyclization of such a class of aromatic Nazarov substrates (entry 2, Table 2). In order to achieve a [6-5-6] tricyclic system with a quarternary stereocenter, our attempt to cyclize **21** was futile presumably due to the steric hindrance caused by a substituted methyl group in the reaction intermediate (entry 3, Table 2). Further increase in catalytic loading and temperature only led to decomposition of the starting material.

Thereafter we turned our attention to further explore this synthetic methodology to attain a varied class of heteroatom impregnated [6-5-5]ABC tricycle skeleton. Towards this objective various heteroaromatic Nazarov substrates **14b-m** and **18** (Table 2) were synthesized essentially following reaction conditions similar to those depicted in eq. 1 and eq. 2 (Scheme 5). The intermediate aldehyde **16** in eq. 2 which is required for the synthesis of substrate **18** was synthesized following standard reaction conditions (see ESI for the scheme†).^{15,16} Synthesized substrates (**14a-m**, **18**) were

Table 2 Results of Nazarov reaction on aryl and heteroaryl polarized substrates^a

Entry	Substrate	Time	Temperature	Product	dr ^b (%)	Yield (%)	
1		1.5 h	rt		12a R = OMe, X = O 12b R = H, X = O 12c R = H, X = S	>99	90
		1 h	rt			>99	91
		1.2 h	rt			>99	87
2		24 h	rt/60 °C	No reaction	—	—	
3		24 h	rt/60 °C	No reaction	—	—	
4		1 min	rt		15b R = OMe, X = O 15c R = OMe, X = S 15d R = H, X = O 15e R = H, X = S	>99	90
		1 min	rt			>99	92
		1 min	rt			>99	92
		1 min	rt			>99	91
5		45 min	rt		15f R = OMe, X = O 15g R = OMe, X = S 15h R = H, X = O	>99	85
		35 min	rt			>99	88
		40 min	rt			>99	87
6		1.5 h	rt		15i R = OMe, X = O 15j R = H, X = S 15k R = H, X = O	>99	84
		1 h	rt			>99	88
		1.3 h	rt			>99	81
7		24 h	rt/60 °C	No reaction	—	—	
8		24 h	rt/60 °C	No reaction	—	—	
9		1.5 h	rt		>99	85	


^a = DCM is used as solvent in all reactions. ^b = determined by NMR/HPLC.

then surveyed under one of the best optimized reaction conditions (triflic acid in DCM) for the desired cyclized products.


Observation of summarized results (Table 2) emphasized that aryl and heteroaryls represented the electron donating vinyl nucleophile in polarized Nazarov cyclization. It also provided information about the extent of polarization in this relatively new class of aromatic/heteroaromatic Nazarov substrates as the 2-substituted thiophene and furan substrates **14l** and **14m** failed to cyclize whereas 3-substituted thiophene substrates **14i**, **14j**, **14k** and **18** gave cyclized products **15i**, **15j**, **15k** and **19** in varying yields (84, 88, 81 and 85% respectively) under similar

reaction conditions. Increasing temperature and catalyst loading gave only uncharacterizable products. In contrast, 2-substituted pyrrole based substrates **14f**, **14g**, and **14h** furnished **15f**, **15g**, and **15h** in good yields (85, 88, and 87% respectively). Indole based Nazarov substrates **14b**, **14c**, **14d**, **14e** gave the desired [6-5-5] tricyclic skeleton embedded novel pentacyclic molecules **15b**, **15c**, **15d**, **15e** under similar reaction conditions in a minute with very high yields (90, 92, 92, 91% respectively).

The structure and stereochemistry of the synthesized cyclic molecules were determined through incisive analysis of ¹H, ¹³C NMR, ¹H-¹H COSY, HSQC spectra. The *cis* relationship between




Scheme 3 Synthesis of Nazarov substrates **10a-c**. ^aReagents and conditions: (a) PBr₃, dry benzene, 60 °C, 24 h, 60–64%. (b) (i) *n*-BuLi, dry THF, –78 °C, N₂, 5–10 min. (ii) **11**, –78 °C to r.t., 2 h, 55–60%. (c) MnO₂, dry ether, r.t., 1 h, 80–85%.



Scheme 4 Aromatic Nazarov cyclization process.

two vicinal protons in the final products was first revealed by the coupling constant ($J = 6\text{--}7$ Hz) from ¹H NMR. This stereochemical assignment was further reinforced by NOESY experiments.

In conclusion we have reported an easy, general and expedient route to access a variety of uncommon hetero [6-5-6]ABC tricyclic cores analogous to Taiwaniaquinoids as well as several hetero [6-5-5] tricyclic systems *via* diastereoselective Nazarov cyclization. This is the first aromatic Nazarov system to show excellent diastereo and regioselectivity under very mild reaction conditions, providing high yielding functionalized scaffolds that could serve as valuable building blocks for diversity oriented synthesis. Their



Scheme 5 Synthesis of new aromatic/heteroaromatic Nazarov substrates following similar reaction conditions as Scheme 3.

bioevaluation and the asymmetric version of the Nazarov reaction on this system are currently underway in our lab and will be reported in due course.

Experimental

General methods

All dry reactions were carried out under argon or nitrogen. Commercial reagents were used without further purification unless otherwise stated. Reactions were monitored on silica gel TLC plates (coated with TLC grade silica gel, obtained from Merck). The detecting agent used (for TLC) was iodine vapors. Column chromatography was performed over silica gel (100–200 mesh) procured from Qualigens (India). Mass spectra were recorded using electron spray ionization (ESI-MS) or fast atom bombardment spectra (FAB-MS) on a JEOL SX 102 spectrometer using Argon/xenon as the FAB gas. Melting points were determined on COMPLAB melting point apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer FT-IR RXI spectrometer. ¹H NMR and ¹³C NMR spectra were recorded on Bruker DPX-200 (operating at 200 MHz for ¹H and 50 MHz for ¹³C) or DPX-300 (operating at 300 MHz for ¹H and 75 MHz for ¹³C) spectrometer using CDCl₃ and CCl₄ as solvent. Tetramethylsilane (0.00 ppm) served as an internal standard in ¹H NMR and CDCl₃ (77.0 ppm) in ¹³C NMR. Coupling constants (J values) are given in hertz (Hz). Chemical shifts are expressed in parts per million.

Experimental procedures and characterization data

Typical procedure to prepare allyl alcohols

(1-Benzyl-1H-indol-2-yl)(7-methoxy-2,2-dimethyl-2H-chromen-4-yl) methanol (13b). To a stirred solution of bromo substrate **8a** (500 mg, 1.85 mmol) in anhydrous THF (20 mL) at $-78\text{ }^{\circ}\text{C}$ and under N_2 , *n*-BuLi (1.6 M in hexane, 1.2 mL, 1.85 mmol) was added. The resulting yellow solution was stirred at $-78\text{ }^{\circ}\text{C}$ for 5–10 minutes after which N-benzyl indole 2-carboxaldehyde (393 mg, 1.66 mmol) in THF (2 mL) were added at the same temperature and stirred at room temperature for 1 h. After quenching with water, THF was removed in vacuo. The mixture was extracted with ethyl acetate (3 \times 20 mL), washed with brine and dried over Na_2SO_4 . The concentrated extract was subjected to column chromatography on silica gel and elution with 20% ethyl acetate in hexane furnished alcohol **13b** (418 mg, 54%) as viscous green oil, $R_f = 0.51$ (AcOEt/hexane, 20:80); IR (Neat): 3417, 3010, 2330, 1211, 759, 670 cm^{-1} ; $^1\text{H NMR}$ (200 MHz, CDCl_3): δ 7.57 (d, 1H, $J = 7.5$), 7.33–7.02 (m, 8H), 6.47 (d, 2H, $J = 7.7$), 6.37 (d, 1H, $J = 2.5$), 6.14–6.10 (m, 1H), 5.71 (s, 1H), 5.67 (s, 1H), 5.54 (s, 2H), 3.71 (s, 3H), 2.00 (s, 1H), 1.46 (s, 3H), 1.43 (s, 3H); MS (FAB): m/z 410 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{28}\text{H}_{27}\text{NO}_3$: C, 79.03; H, 6.40; N, 3.29. Found: C, 78.95; H, 6.34; N, 3.35.

(1-Benzyl-1H-indol-2-yl)(7-methoxy-2, 2-dimethyl-2H-thiochromen-4-yl) methanol (13c). As described for **13b**, **8d** (500 mg, 1.75 mmol) in THF (20 mL), *n*-BuLi (1.1 mL, 1.75 mmol), N-benzyl indole 2-carboxaldehyde (372 mg, 1.57 mmol) in THF (2 mL) furnished **13c** (410 mg, 53%) as viscous colorless oil, $R_f = 0.53$ (AcOEt/hexane, 20:80); IR (Neat): 3409, 3020, 2360, 1216, 762, 670 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.60 (d, 1H, $J = 7.8$), 7.52 (d, 1H, $J = 8.8$), 7.30–7.24 (m, 4H), 7.15–7.04 (m, 6H), 6.81 (d, 1H, $J = 1.1$), 6.64 (dd, 1H, $J_1 = 2.5$, $J_2 = 8.7$), 6.72 (d, 1H, $J = 2.5$), 5.39 (s, 2H), 3.78 (s, 3H), 1.26 (s, 3H), 0.98 (s, 3H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3): δ 158.8, 150.1, 149.1, 140.6, 137.3, 134.8, 128.8, 127.5, 126.5, 126.2, 124.8, 123.0, 120.1, 120.0, 118.8, 17.5, 112.9, 112.3, 110.3, 55.3, 55.1, 48.9, 48.3, 29.6, 22.8; MS (ESI): m/z 424 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{28}\text{H}_{27}\text{NO}_2\text{S}$: C, 76.16; H, 6.16; N, 3.17. Found: C, 76.09; H, 6.24; N, 3.28.

(1-Benzyl-1H-indol-2-yl)(2,2-dimethyl-2H-chromen-4-yl)methanol (13d). As described for **13b**, **8b** (500 mg, 2.09 mmol) in THF (20 mL), *n*-BuLi (1.3 mL, 2.09 mmol), N-benzyl indole 2-carboxaldehyde (594 mg, 1.88 mmol) in THF (2 mL) furnished **13d** (471 mg, 57%) as viscous colorless oil, $R_f = 0.54$ (AcOEt/hexane, 20:80); IR (Neat): 3429, 3021, 2359, 1620, 1218, 765 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.59 (d, 2H, $J = 7.7$), 7.35–7.20 (m, 5H), 7.16–7.03 (m, 4H), 6.58 (d, 2H, $J = 4.1$), 6.49 (s, 1H), 5.89 (d, 1H, $J = 1.1$), 5.74 (s, 1H), 5.61 (d, 1H, $J = 16.9$), 5.53 (d, 1H, $J = 16.8$), 2.02 (s, br, 1H), 1.51 (s, 3H), 1.47 (s, 3H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3): δ 152.7, 139.5, 138.2, 137.8, 129.0, 128.8, 127.6, 127.5, 127.2, 126.2, 123.5, 122.4, 121.1, 120.4, 120.2, 119.8, 116.6, 109.6, 102.6, 75.9, 65.3, 46.9, 27.7, 27.6; MS (ESI): m/z 396 $[\text{M} + 1]^+$, 378 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{27}\text{H}_{25}\text{NO}_2$: C, 82.00; H, 6.37; N, 3.54. Found: C, 81.92; H, 6.45; N, 3.61.

(1-Benzyl-1H-pyrrol-2-yl)(2,2-dimethyl-2H-chromen-4-yl)methanol (13f). As described for **13b**, **8a** (500 mg, 1.85 mmol) in

THF (20 mL), *n*-BuLi (1.2 mL, 1.85 mmol), N-benzylpyrrole 2-carboxaldehyde (308 mg, 1.67 mmol) in THF (2 mL) furnished **13f** (339 mg, 53%) as viscous colorless oil, $R_f = 0.45$ (AcOEt/hexane, 20:80); IR (Neat): 3419, 3021, 2360, 1211, 761, 670 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.33–7.23 (m, 3H), 7.12–7.10 (m, 2H), 7.03–6.97 (m, 1H), 6.76–6.74 (m, 2H), 6.57–6.52 (m, 1H), 6.40 (dd, 1H, $J_1 = 1.4$, $J_2 = 7.7$), 6.07–6.01 (m, 2H), 5.82 (d, 1H, $J = 1.2$), 5.48 (s, 1H), 5.35 (d, 1H, $J = 16.0$), 5.17 (d, 1H, $J = 16.0$), 1.83 (s, br, 1H), 1.44 (s, 3H), 1.42 (s, 3H); MS (ESI): m/z 328 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{23}\text{H}_{23}\text{NO}_2$: C, 79.97; H, 6.71; N, 4.05. Found: C, 79.88; H, 6.79; N, 3.93.

(3,4-Dimethoxyphenyl)(7-methoxy-2,2-dimethyl-2H-chromen-4-yl)methanol (9a). As described for **13b**, **8a** (500 mg, 1.85 mmol) in THF (20 mL), *n*-BuLi (1.2 mL, 1.85 mmol), veratraldehyde (276 mg, 1.66 mmol) in THF (2 mL) furnished **9a** (364 mg, 55%) as viscous colorless oil, $R_f = 0.61$ (AcOEt/hexane, 20:80); IR (Neat): 3431, 2360, 1560, 1217, 761, 670 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, $\text{CDCl}_3 + \text{CCl}_4$): δ 6.95–6.91 (m, 2H), 6.87 (d, 1H, $J = 8.6$), 6.80 (d, 1H, $J = 7.9$), 6.36 (d, 1H, $J = 2.5$), 6.26 (dd, 1H, $J_1 = 2.6$, $J_2 = 8.6$), 5.68 (s, 1H), 5.53 (s, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.72 (s, 3H), 2.03 (s, br, 1H), 1.47 (s, 6H); $^{13}\text{C NMR}$ (75 MHz, $\text{CDCl}_3 + \text{CCl}_4$): δ 160.4, 154.5, 149.2, 148.8, 134.4, 133.3, 124.8, 124.8, 119.5, 113.4, 111.2, 110.3, 106.5, 102.2, 76.0, 72.6, 55.8, 5.7, 55.0, 27.9; MS (ESI): m/z 339 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{21}\text{H}_{24}\text{O}_5$: C, 70.77; H, 6.79. Found: C, 70.65; H, 6.85.

(3,4-Dimethoxyphenyl)(2,2-dimethyl-2H-chromen-4-yl)methanol (9b). As described for **13b**, **8b** (500 mg, 2.09 mmol) in THF (20 mL), *n*-BuLi (1.3 mL, 2.09 mmol), veratraldehyde (312 mg, 1.88 mmol) in THF (2 mL) furnished **9b** (409 mg, 60%) as viscous colorless oil, $R_f = 0.59$ (AcOEt/hexane, 20:80); IR (Neat): 3414, 3021, 2358, 1591, 1216, 758, 668 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, $\text{CDCl}_3 + \text{CCl}_4$): δ 7.00–6.94 (m, 1H), 6.91–6.85 (m, 3H), 6.75–6.60 (m, 3H), 5.70 (s, 1H), 5.52 (s, 1H), 3.78 (s, 3H), 3.77 (s, 3H), 1.86 (s, br, 1H), 1.40 (s, 6H); $^{13}\text{C NMR}$ (75 MHz, $\text{CDCl}_3 + \text{CCl}_4$): δ 153.1, 149.2, 148.9, 134.2, 133.4, 129.0, 127.5, 123.9, 120.5, 120.2, 119.5, 116.8, 111.1, 110.2, 75.7, 72.5, 55.8, 55.7, 27.9; MS (ESI): m/z 309 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{20}\text{H}_{22}\text{O}_4$: C, 73.60; H, 6.79. Found: C, 73.71; H, 6.90.

(3,4-Dimethoxyphenyl)(2,2-dimethyl-2H-thiochromen-4-yl)methanol (9c). As described for **13b**, **8c** (500 mg, 1.96 mmol) in THF (20 mL), *n*-BuLi (1.2 mL, 1.96 mmol), veratraldehyde (293 mg, 1.76 mmol) in THF (2 mL) furnished **9c** (395 mg, 59%) as viscous colorless oil, $R_f = 0.48$ (AcOEt/hexane, 20:80); IR (Neat): 3430, 3020, 2331, 1571, 1212, 760, 660 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, $\text{CDCl}_3 + \text{CCl}_4$): δ 7.30–7.27 (m, 1H), 7.19 (dd, 1H, $J_1 = 1.0$, $J_2 = 7.8$), 7.09–7.03 (m, 1H), 6.99–6.91 (m, 3H), 6.81–6.79 (m, 1H), 6.12 (s, 1H), 5.66 (s, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 2.10 (s, br, 1H), 1.49 (s, 3H), 1.47 (s, 3H); $^{13}\text{C NMR}$ (75 MHz, $\text{CDCl}_3 + \text{CCl}_4$): δ 149.1, 148.6, 137.0, 134.8, 133.1, 132.8, 130.8, 127.9, 127.4, 127.3, 125.4, 119.4, 111.1, 110.2, 55.7, 55.6, 40.2, 28.9. MS (ESI): m/z 325 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{20}\text{H}_{22}\text{O}_3\text{S}$: C, 70.15; H, 6.48. Found: C, 70.22; H, 6.57.

(7-Methoxy-2,2-dimethyl-2H-chromen-4-yl)(thiophen-3-yl)methanone (13i). As described for **13b**, **8a** (500 mg, 1.85 mmol) in THF (20 mL), *n*-BuLi (1.2 mL, 1.85 mmol), thiophene 3-carboxaldehyde (186 mg, 1.66 mmol) in THF (2 mL) furnished **13i** (320 mg, 57%) as viscous colorless oil, $R_f = 0.50$ (AcOEt/hexane,

20:80); IR (Neat): 3434, 3020, 1217, 760 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.29–7.24 (m, 2H), 7.06 (dd, 1H, $J_1 = 1.3$, $J_2 = 4.9$), 6.96 (d, 1H, $J = 8.6$), 6.39 (d, 1H, $J = 2.5$), 6.31 (dd, 1H, $J_1 = 2.5$, $J_2 = 8.5$), 5.65 (s, 2H), 3.74 (s, 3H), 2.26 (s, br, 1H), 1.47 (s, 3H), 1.47 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ 160.5, 154.5, 143.4, 133.4, 126.6, 124.8, 124.7, 122.4, 113.3, 106.5, 102.3, 76.1, 69.3, 55.0, 27.9, 27.8; MS (ESI): m/z 285 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{17}\text{H}_{18}\text{O}_3\text{S}$: C, 67.52; H, 6.00. Found: C, 67.42; H, 5.91.

(2,2-Dimethyl-2H-thiochromen-4-yl)thiophen-3-ylmethanol (13j).

As described for **13b**, **8c** (500 mg, 1.96 mmol) in THF (20 ml), *n*-BuLi (1.2 ml, 1.96 mmol), thiophene 3-carboxaldehyde (197 mg, 1.76 mmol) in THF (2 mL) furnished **13j** (305 mg, 54%) as viscous colorless oil, $R_f = 0.52$ (AcOEt/hexane, 20:80); IR (Neat): 3443, 3020, 2330, 1211, 759 cm^{-1} ; ^1H NMR (300 MHz, $\text{CDCl}_3 + \text{CCl}_4$): δ 7.22–7.16 (m, 3H), 7.12–7.11 (m, 1H), 7.02–6.88 (m, 3H), 5.98 (s, 1H), 5.68 (s, 1H), 1.96 (s, br, 1H), 1.39 (s, 3H), 1.37 (s, 3H); ^{13}C NMR (75 MHz, $\text{CDCl}_3 + \text{CCl}_4$): δ 144.0, 137.3, 133.3, 132.8, 130.7, 128.0, 127.5, 126.7, 125.3, 125.1, 122.4, 71.1, 40.2, 29.1, 29.0; MS (ESI): m/z 271 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{16}\text{H}_{16}\text{OS}_2$: C, 66.63; H, 5.59. Found: C, 66.54; H, 5.51.

(2,2-Dimethyl-2H-chromen-4-yl)(thiophen-3-yl)methanol (13k).

As described for **13b**, **8b** (500 mg, 2.09 mmol) in THF (20 ml), *n*-BuLi (1.3 ml, 2.09 mmol), thiophene 3-carboxaldehyde (210 mg, 1.88 mmol) in THF (2 mL) furnished **13k** (313 mg, 55%) as viscous colorless oil, $R_f = 0.53$ (AcOEt/hexane, 20:80); IR (Neat): 3404, 3021, 2359, 1216, 760 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.30–7.26 (m, 2H), 7.14–7.06 (m, 3H), 6.85–6.73 (m, 2H), 5.81 (s, 1H), 5.72 (s, 1H), 2.38 (s, br, 1H), 1.47 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 153.0, 143.2, 133.4, 129.0, 127.4, 126.5, 126.1, 123.7, 122.6, 120.4, 120.1, 116.7, 75.7, 68.9, 27.7, 27.6; MS (ESI): m/z 255 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{16}\text{H}_{16}\text{O}_2\text{S}$: C, 70.56; H, 5.92. Found: C, 70.67; H, 6.05.

(2,2-Dimethyl-2H-chromen-4-yl)(phenyl)methanol (13a). As described for **13b**, **8b** (500 mg, 1.85 mmol) in THF (20 ml), *n*-BuLi (1.2 ml, 1.85 mmol), benzaldehyde (176 mg, 1.66 mmol) in THF (2 mL) furnished **13a** (322 mg, 58%) as viscous colorless oil, $R_f = 0.56$ (AcOEt/hexane, 20:80); IR (Neat): 3430, 3019, 2360, 1210, 759, 669 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.48 (d, 1H, $J = 1.6$), 7.45 (d, 1H, $J = 1.0$), 7.41–7.29 (m, 3H), 7.12–7.03 (m, 2H), 6.83 (dd, 1H, $J_1 = 1.0$, $J_2 = 8.0$), 6.75 (m, 1H), 5.84 (d, 1H, $J = 1.2$), 5.69 (d, 1H, $J = 2.5$), 2.17 (d, 1H, $J = 3.8$), 1.50 (s, 3H), 1.50 (s, 3H); MS (ESI): m/z 249 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{18}\text{H}_{18}\text{O}_2$: C, 81.17; H, 6.81; Found: C, 81.19; H, 6.91.

(7-Methoxy-2, 2-dimethyl-2H-chromen-4-yl)(5-methylfuran-2-yl)methanol (13m). As described for **13b**, **8a** (500 mg, 1.85 mmol) in THF (20 ml), *n*-BuLi (1.2 ml, 1.85 mmol), 5-methyl furfural (183 mg, 1.66 mmol) in THF (2 mL) furnished **13m** (312 mg, 56%) as viscous colorless oil, $R_f = 0.52$ (AcOEt/hexane, 20:80); IR (Neat): 3432, 3023, 2360, 1213, 760, cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 6.98 (d, 1H, $J = 8.4$), 6.43 (d, 1H, $J = 2.5$), 6.36 (dd, 1H, $J_1 = 2.5$, $J_2 = 8.5$), 6.07 (d, 1H, $J = 2.8$), 5.89 (d, 1H, $J = 2.1$), 5.77 (d, 1H, $J = 0.8$), 5.65 (s, 1H), 3.77 (s, 3H), 2.31 (s, 3H), 2.17 (s, br, 1H), 1.47 (s, 6H); MS (ESI): m/z 283 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{18}\text{H}_{20}\text{O}_4$: C, 71.98; H, 6.71; Found: C, 72.90; H, 6.59.

(3,4-Dimethoxyphenyl)(7-methoxy-2, 2,3-trimethyl-2H-chromen-4-yl)methanol (20). As described for **13b**, **22** (500 mg,

1.76 mmol) in THF (20 ml), *n*-BuLi (1.1 ml, 1.76 mmol), veratraldehyde (263 mg, 1.58 mmol) in THF (2 mL) furnished **20** (379 mg, 58%) as viscous colorless oil, $R_f = 0.44$ (AcOEt/hexane, 20:80); IR (Neat): 3430, 3021, 2323, 1213, 759, 661 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.04 (s, 1H), 6.96 (d, 1H, $J = 8.6$), 6.86–6.77 (m, 3H), 6.36 (d, 1H, $J = 2.2$), 6.24 (dd, 1H, $J_1 = 2.0$, $J_2 = 8.5$), 5.96 (s, 1H), 3.85 (s, 6H), 3.72 (s, 3H), 1.86 (s, 3H), 1.48 (s, 3H), 1.41 (s, 3H); MS (ESI): m/z 353 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{22}\text{H}_{26}\text{O}_5$: C, 71.33; H, 7.07; Found: C, 71.45; H, 6.96.

(1-Benzyl-2,2-dimethyl-1,2-dihydroquinolin-4-yl)thiophen-3-ylmethanol (17). As described for **13b**, **15** (500 mg, 3.06 mmol) in THF (20 ml), *n*-BuLi (1.9 ml, 3.06 mmol), **16** (762 mg, 2.75 mmol) in THF (2 mL) furnished **17** (631 mg, 57%) as viscous colorless oil, $R_f = 0.49$ (AcOEt/hexane, 20:80); IR (Neat): 3433, 3021, 2359, 1210, 760, 671 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.24–7.10 (m, 7H), 7.07–7.05 (m, 1H), 6.93 (d, 1H, $J = 6.8$), 6.82–6.76 (m, 1H), 6.39 (t, 1H, $J = 7.3$), 6.22 (d, 1H, $J = 8.2$), 5.70 (s, 1H), 5.64 (s, 1H), 4.51–4.38 (m, 2H), 1.99 (s, br, 1H), 1.35 (s, 3H), 1.33 (s, 3H); MS (ESI): m/z 344 $[\text{M} - \text{OH}]^+$; Anal. Calcd. for $\text{C}_{23}\text{H}_{23}\text{NOS}$: C, 76.42; H, 6.41; N, 3.87. Found: C, 76.33; H, 6.56; N, 3.75.

Typical procedure for the oxidation of allylic alcohols

2H-Chromen (1-benzyl-1H-indol-2-yl) (7-methoxy-2, 2-dimethyl-4-yl)methanone (14b). To a stirred solution of substrate **13b** (300 mg, 0.70 mmol) in dry ether (50 ml) at room temperature, was added activated MnO_2 (613 mg, 7.05 mmol) and the reaction was stirred for 2 h. It was filtered through celite, concentrated *in vacuo* and was subjected to column chromatography on silica gel and elution with 10% ethyl acetate in hexane furnished the desired product **14b** (229 mg, 77%) as colorless semi solid, $R_f = 0.61$ (AcOEt/hexane, 10:90); IR (KBr): 3018, 2920, 1614, 1276, 1142, 757 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.69 (d, 1H, $J = 8.0$), 7.42–7.32 (m, 2H), 7.24–7.08 (m, 8H), 6.44–6.36 (m, 2H), 5.88 (s, 1H), 5.87 (s, 2H), 3.76 (s, 3H), 1.50 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 187.4, 161.1, 154.0, 140.5, 138.2, 134.9, 133.4, 132.6, 128.5, 127.2, 126.6, 126.5, 126.3, 125.8, 123.2, 121.1, 115.8, 112.3, 110.9, 107.0, 102.3, 75.7, 55.2, 48.0, 27.2. MS (ESI): m/z 424 $[\text{M} + 1]^+$, 91 $[\text{C}_6\text{H}_5\text{CH}_2]^+$; Anal. Calcd. for $\text{C}_{28}\text{H}_{25}\text{NO}_3$: C, 79.41; H, 5.95; N, 3.31. Found: C, 79.49; H, 5.88; N, 3.40.

(1-Benzyl-1H-indol-2-yl)(7-methoxy-2,2-dimethyl-2H-thiochromen-4-yl)methanone (14c). As described for **14b**, **13c** (300 mg, 0.68 mmol) in dry ether (50 ml), MnO_2 (591 mg, 6.80 mmol) furnished **14c** (236 mg, 79%) as colorless semi solid, $R_f = 0.64$ (AcOEt/hexane, 10:90); IR (KBr): 2925, 2358, 1710, 1594, 1210, 757 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.69 (d, 1H, $J = 7.7$), 7.46–7.24 (m, 5H), 7.20–7.05 (m, 5H), 6.90 (d, 1H, $J = 3.6$ Hz), 6.56 (dd, 1H, $J_1 = 2.6$, $J_2 = 3.6$), 6.06 (s, 1H), 5.92 (s, 2H), 3.80 (s, 3H), 1.52 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 189.3, 159.2, 140.5, 138.3, 137.8, 135.7, 135.1, 133.9, 128.5, 128.1, 127.2, 126.6, 126.4, 125.9, 123.3, 123.2, 121.0, 116.2, 112.6, 111.6, 110.8, 55.2, 48.0, 40.8, 28.5; MS (ESI): m/z 440 $[\text{M} + 1]^+$; Anal. Calcd. for $\text{C}_{28}\text{H}_{25}\text{NO}_2\text{S}$: C, 76.51; H, 5.73; N, 3.19. Found: C, 76.59; H, 5.82; N, 3.25.

(1-Benzyl-1H-indol-2-yl)(2,2-dimethyl-2H-chromen-4-yl)methanone (14d). As described for **14b**, **13d** (300 mg, 0.76 mmol) in dry ether (50 ml), MnO_2 (659 mg, 7.59 mmol) furnished **14d** (241 mg, 81%) as colorless semi solid, $R_f = 0.62$ (AcOEt/hexane, 10:90);

IR (KBr): 3020, 2360, 1730, 1637, 1260, 1216, 761, 669 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.72 (d, 1H, $J = 8.0$), 7.43–7.39 (m, 2H), 7.28–7.12 (m, 9H), 6.90–6.81 (m, 2H), 6.02 (s, 1H), 5.92 (s, 2H), 1.55 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 187.3, 152.6, 140.6, 138.2, 134.9, 133.7, 129.9, 128.5, 127.2, 126.6, 125.9, 125.4, 123.2, 121.1, 120.9, 119.1, 117.0, 116.0, 110.9, 75.3, 48.1, 27.2; MS (ESI): m/z 394 $[\text{M} + 1]^+$; Anal. Calcd. for $\text{C}_{27}\text{H}_{23}\text{NO}_2$: C, 82.42; H, 5.89; N, 3.56. Found: C, 82.35; H, 5.97; N, 3.65.

(1-Benzyl-1H-indol-2-yl)(2,2-dimethyl-2H-thiochromen-4-yl)methanone (14e). As described for **14b**, **13e** (300 mg, 0.73 mmol) in dry ether (50 ml), MnO_2 (633 mg, 7.29 mmol) furnished **14e** (250 mg, 84%) as colorless semi solid, $R_f = 0.67$ (AcOEt/hexane, 10:90); IR (KBr): 3020, 2925, 2360, 1726, 1638, 1216, 761, 670 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.68 (d, 1H, $J = 7.8$ Hz), 7.43–7.34 (m, 3H), 7.29–7.27 (m, 3H), 7.19–7.09 (m, 6H), 7.01–6.99 (m, 1H), 6.17 (s, 1H), 5.92 (s, 2H), 1.51 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 189.1, 140.6, 138.3, 137.8, 135.1, 132.2, 130.1, 128.5, 128.3, 127.9, 127.2, 126.9, 126.7, 126.6, 125.9, 125.4, 123.3, 121.1, 116.4, 48.0, 40.4, 28.5; MS (ESI): m/z 410 $[\text{M} + 1]^+$; Anal. Calcd. for $\text{C}_{27}\text{H}_{23}\text{NOS}$: C, 79.18; H, 5.66; N, 3.42. Found: C, 79.27; H, 5.71; N, 3.33.

(1-Benzyl-1H-pyrrol-2-yl)(7-methoxy-2,2-dimethyl-2H-chromen-4-yl)methanone (14f). As described for **14b**, **13f** (300 mg, 0.80 mmol) in dry ether (50 ml), MnO_2 (695 mg, 8.00 mmol) furnished **14f** (244 mg, 81%) as colorless semi solid, $R_f = 0.67$ (AcOEt/hexane, 10:90); IR (KBr): 3021, 2361, 1730, 1606, 1216, 1045, 761 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.36–7.17 (m, 5H), 7.11 (d, 1H, $J = 8.4$), 7.03–7.01 (m, 2H), 6.92 (dd, 1H, $J_1 = 1.5$, $J_2 = 3.9$), 6.45–6.36 (m, 2H), 6.20–6.17 (m, 1H), 5.77 (s, 1H), 5.67 (s, 2H), 3.76 (s, 3H), 1.50 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 184.8, 160.9, 154.0, 138.0, 133.3, 131.6, 130.4, 130.2, 128.5, 127.5, 127.2, 126.1, 123.5, 112.6, 198.6, 106.8, 102.2, 75.6, 55.2, 52.5, 27.3; MS (ESI): m/z 374 $[\text{M} + 1]^+$; Anal. Calcd. for $\text{C}_{24}\text{H}_{23}\text{NO}_3$: C, 77.19; H, 6.21; N, 3.75. Found: C, 77.10; H, 6.31; N, 3.81.

(1-Benzyl-1H-pyrrol-2-yl)(7-methoxy-2,2-dimethyl-2H-thiochromen-4-yl)methanone (14g). As described for **14b**, **13g** (300 mg, 0.76 mmol) in dry ether (50 ml), MnO_2 (667 mg, 7.67 mmol) furnished **14g** (253 mg, 85%) as colorless semi solid, $R_f = 0.66$ (AcOEt/hexane, 10:90); IR (KBr): 3020, 2359, 1681, 1220, 759, 670 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.35–7.14 (m, 5H), 7.01–6.96 (m, 2H), 6.82 (d, 1H, $J = 2.4$), 6.77–6.75 (m, 1H), 6.55–6.49 (m, 1H), 6.14–6.11 (m, 1H), 5.89 (s, 1H), 5.64 (s, 2H), 3.75 (s, 3H), 1.45 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 186.5, 159.0, 138.0, 137.5, 133.7, 133.6, 131.4, 130.6, 128.5, 127.9, 127.2, 123.9, 123.4, 112.3, 111.5, 108.6, 55.2, 52.5, 40.6, 28.6; MS (ESI): m/z 390 $[\text{M} + 1]^+$; Anal. Calcd. for $\text{C}_{24}\text{H}_{23}\text{NO}_2\text{S}$: C, 74.00; H, 5.95; N, 3.60. Found: C, 74.07; H, 5.88; N, 3.52.

(3,4-Dimethoxyphenyl)(7-methoxy-2,2-dimethyl-2H-chromen-4-yl)methanone (10a). As described for **14b**, **9a** (300 mg, 0.84 mmol) in dry ether (50 ml), MnO_2 (732 mg, 8.42 mmol) furnished **10a** (244 mg, 82%) as colorless semi solid, $R_f = 0.71$ (AcOEt/hexane, 10:90); IR (KBr): ν 3021, 2361, 1730, 1217, 761, 670 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.54 (d, 1H, $J = 1.8z$), 7.48 (dd, 1H, $J_1 = 1.8$, $J_2 = 8.3$), 7.12 (d, 1H, $J = 8.4$), 6.85 (d, 1H, $J = 8.3$), 6.44–6.37 (m, 2H), 5.70 (s, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 3.79 (s, 3H), 1.53 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 193.9, 161.0, 153.9, 153.4, 148.9, 132.5, 131.2, 129.9, 126.3, 125.3,

112.4, 111.2, 109.7, 106.9, 102.3, 75.7, 55.9, 55.8, 55.1; MS (ESI): m/z 355 $[\text{M} + 1]^+$; Anal. Calcd. for $\text{C}_{21}\text{H}_{22}\text{O}_5$: C, 71.17; H, 6.26. Found: C, 71.29; H, 6.17.

(3,4-Dimethoxyphenyl)(2,2-dimethyl-2H-chromen-4-yl)methanone (10b). As described for **14b**, **9b** (300 mg, 0.92 mmol) in dry ether (50 ml), MnO_2 (800 mg, 6.80 mmol) furnished **10b** (253 mg, 85%) as colorless semi solid, $R_f = 0.72$ (AcOEt/hexane, 10:90); IR (KBr): 3020, 2361, 1724, 1591, 1216, 760, 668 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.55 (d, 1H, $J = 1.9$), 7.50 (dd, 1H, $J_1 = 2.0$, $J_2 = 8.3$), 7.20–7.14 (m, 2H), 6.88–6.80 (m, 3H), 5.87 (s, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 1.52 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 193.9, 153.7, 152.5, 149.09, 133.7, 132.9, 130.0, 129.9, 125.5, 125.4, 121.0, 119.3, 117.0, 111.3, 109.9, 75.4, 56.1, 55.9, 27.3. MS (ESI): m/z 325 $[\text{M} + 1]^+$. Anal. Calcd. for $\text{C}_{20}\text{H}_{20}\text{O}_4$: C, 74.06; H, 6.21. Found: C, 74.17; H, 6.15.

(3,4-Dimethoxyphenyl)-(2,2-dimethyl-2H-thiochromen-4-yl)methanone (10c). As described for **14b**, **9c** (300 mg, 0.87 mmol) in dry ether (50 ml), MnO_2 (762 mg, 8.77 mmol) furnished **10c** (235 mg, 79%) as colorless semi solid, $R_f = 0.75$ (AcOEt/hexane, 10:90); IR (KBr): 3021, 2361, 1732, 1268, 1217, 758, 668 cm^{-1} ; ^1H NMR (300 MHz, $\text{CDCl}_3 + \text{CCl}_4$): δ 7.45 (d, 1H, $J = 1.8$), 7.34–7.30 (m, 2H), 7.16–7.11 (m, 2H), 7.03–6.98 (m, 1H), 6.78 (d, 1H, $J = 8.4$), 6.01 (s, 1H), 3.90 (s, 3H), 3.88 (s, 3H), 1.49 (s, 6H); ^{13}C NMR (75 MHz, $\text{CDCl}_3 + \text{CCl}_4$): δ 195.1, 153.6, 149.1, 137.9, 136.5, 132.1, 130.2, 130.0, 128.3, 128.0, 126.9, 125.6, 125.5, 111.6, 110.0, 55.9, 55.8, 40.5, 28.6; MS (ESI): m/z 341 $[\text{M} + 1]^+$; Anal. Calcd. for $\text{C}_{20}\text{H}_{20}\text{O}_3\text{S}$: C, 70.56; H, 5.92. Found: C, 70.65; H, 6.02.

(7-Methoxy-2,2-dimethyl-2H-chromen-4-yl)thiophen-3-ylmethanone (14i). As described for **14b**, **13i** (300 mg, 0.99 mmol) in dry ether (50 ml), MnO_2 (863 mg, 9.93 mmol) furnished **14i** (223 mg, 75%) as colorless semi solid, $R_f = 0.68$ (AcOEt/hexane, 10:90); IR (KBr): 3020, 236, 1731, 1651, 1614, 1218, 764 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.95 (dd, 1H, $J_1 = 1.1$, $J_2 = 2.9$), 7.55 (dd, 1H, $J_1 = 1.1$, $J_2 = 5.0$), 7.33–7.30 (m, 1H), 7.26–7.23 (m, 1H), 6.41–6.37 (m, 2H), 5.86 (s, 1H), 3.77 (s, 3H), 1.50 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 188.2, 161.4, 154.2, 142.0, 134.2, 133.5, 131.9, 128.2, 126.5, 126.2, 112.0, 107.1, 102.6, 75.6, 55.2, 27.4; MS (ESI): m/z 301 $[\text{M} + 1]^+$; Anal. Calcd. for $\text{C}_{17}\text{H}_{16}\text{O}_3\text{S}$: C, 67.98; H, 5.37. Found: C, 68.06; H, 5.48.

(2,2-Dimethyl-2H-thiochromen-4-yl) thiophen-3-ylmethanone (14j). As described for **14b**, **13j** (300 mg, 1.04 mmol) in dry ether (50 ml), MnO_2 (905 mg, 10.4 mmol) furnished **14j** (229 mg, 77%) as colorless semi solid, $R_f = 0.65$ (AcOEt/hexane, 10:90); ^1H NMR (300 MHz, CDCl_3): δ 7.78–7.77 (m, 1H), 7.42–7.41 (m, 1H), 7.28–7.25 (m, 1H), 7.22–7.18 (m, 2H), 7.12–7.06 (m, 1H), 7.00–6.95 (m, 1H), 6.07 (s, 1H), 1.42 (s, 6H); MS (ESI): m/z 303 $[\text{M} + \text{NH}_4]^+$; Anal. Calcd. for $\text{C}_{16}\text{H}_{14}\text{OS}_2$: C, 67.10; H, 4.93. Found: C, 67.16; H, 5.03.

(2,2-Dimethyl-2H-chromen-4-yl)(thiophen-3-yl)methanone (14k). As described for **14b**, **13k** (300 mg, 1.10 mmol) in dry ether (50 ml), MnO_2 (958 mg, 11.0 mmol) furnished **14k** (232 mg, 77%) as colorless semi solid, $R_f = 0.63$ (AcOEt/hexane, 10:90); ^1H NMR (300 MHz, CDCl_3): δ 7.90–7.89 (m, 1H), 7.51–7.49 (m, 1H), 7.28–7.25 (m, 1H), 7.22–7.18 (m, 2H), 7.12–7.06 (m, 1H), 7.00–6.95 (m, 1H), 5.92 (s, 1H), 1.45 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3): δ 193.9, 161.0, 153.9, 153.4, 148.9, 132.5, 131.2, 129.9, 126.3, 125.3,

112.4, 111.2, 109.7, 106.9, 102.3, 75.7, 55.9, 55.8, 55.1, 27.2; MS (ESI): m/z 271 [M + 1]⁺; Anal. Calcd. for C₁₆H₁₄O₂S: C, 71.08; H, 5.22. Found: C, 71.16; H, 5.13.

1-Benzyl-2,2-dimethyl-1,2-dihydroquinoline-4-carbaldehyde (16).

To a stirred solution of N-benzyl-2,2,4-trimethyl-1,2-dihydroquinoline (580 mg, 2.196 mmol) in anhydrous dioxane (44 ml) was added SeO₂ (365.66 mg, 3.295 mmol). It was then heated to reflux and stirred for 2 h. The mixture was filtered through celite, concentrated *in vacuo* and was subjected to column chromatography on silica gel and elution with 10% ethyl acetate in hexane furnished the desired product **16** (250 mg, 41–45%) as a viscous yellow oil. R_f = 0.55; ¹H NMR (300 MHz, CDCl₃): δ 9.70 (s, 1H), 8.14 (dd, 1H, J_1 = 1.2, J_2 = 7.7), 7.23–7.13 (m, 5H), 6.95–6.90 (m, 1H), 6.62–6.57 (m, 1H), 6.29 (d, 1H, J = 8.3), 6.20 (s, 1H), 4.45 (s, 2H), 1.41 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 192.2, 151.6, 143.7, 138.9, 132.4, 130.0, 128.6, 126.7, 126.0, 125.7, 116.9, 116.7, 112.9, 57.4, 47.8, 27.3; MS (ESI): m/z 278 [M + 1]⁺; Anal. Calcd. for C₁₉H₁₉NO: C, 82.28; H, 6.90; N, 5.05. Found: C, 82.19; H, 6.81; N, 4.95.

(2,2-Dimethyl-2H-chromen-4-yl)(phenyl)methanone (14a). As described for **14b**, **13a** (300 mg, 1.18 mmol) in dry ether (50 ml), MnO₂ (1.03 g, 11.8 mmol) furnished **14a** (235 mg, 79%) as colorless semi solid, R_f = 0.65 (AcOEt/hexane, 10:90); ¹H NMR (300 MHz, CDCl₃+CCl₄): δ 7.92–7.90 (m, 2H), 7.63–7.58 (m, 1H), 7.50–7.45 (m, 2H), 7.30 (dd, 1H, J_1 = 1.5, J_2 = 7.6), 7.23–7.14 (m, 1H), 6.91–6.83 (m, 2H), 5.95 (s, 1H), 1.53 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 195.1, 152.6, 137.2, 135.6, 133.2, 132.8, 130.0, 129.9, 128.5, 125.7, 121.0, 119.1, 117.0, 75.4, 27.3; MS (ESI): m/z 252 [M + 1]⁺; Anal. Calcd. for C₁₇H₁₅O₂: C, 81.25; H, 6.02. Found: C, 81.16; H, 5.93.

(7-Methoxy-2,2-dimethyl-2H-chromen-4-yl)(thiophen-2-yl) methanone (14l). As described for **14b**, **13l** (300 mg, 0.99 mmol) in dry ether (50 ml), MnO₂ (863 mg, 9.93 mmol) furnished **14l** (235 mg, 79%) as colorless semi solid, R_f = 0.65 (AcOEt/hexane, 10:90); ¹H NMR (300 MHz, CDCl₃): δ 7.72–7.68 (m, 2H), 7.30 (d, 1H, J = 7.9), 7.15–7.12 (m, 1H), 6.46–6.42 (m, 2H), 5.96 (s, 1H), 3.79 (s, 3H), 1.53 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 186.9, 161.3, 154.1, 144.0, 134.8, 134.6, 132.6, 132.0, 128.0, 126.3, 111.8, 107.1, 102.5, 75.7, 55.3, 27.2; MS (ESI): m/z 301 [M + 1]⁺; Anal. Calcd. for C₁₇H₁₆O₃S: C, 67.98; H, 5.37. Found: C, 68.10; H, 5.29.

(7-Methoxy-2,2-dimethyl-2H-chromen-4-yl)(5-methylfuran-2-yl)methanone (14m). As described for **14b**, **13m** (300 mg, 1.0 mmol) in dry ether (50 ml), MnO₂ (869 mg, 10.0 mmol) furnished **14m** (238 mg, 80%) as colorless semi solid, R_f = 0.69 (AcOEt/hexane, 10:90); ¹H NMR (300 MHz, CDCl₃): δ 7.31 (d, 1H, J = 9.0), 7.04 (d, 1H, J = 3.4), 6.44–6.40 (m, 2H), 6.15 (d, 1H, J = 3.0), 5.94 (s, 1H), 3.76 (s, 3H), 2.42 (s, 3H), 1.50 (s, 6H); MS (ESI): m/z 299 [M + 1]⁺; Anal. Calcd. for C₁₈H₁₈O₄: C, 72.47; H, 6.08. Found: C, 72.36; H, 5.93.

(3,4-Dimethoxyphenyl)(7-methoxy-2,2,3-trimethyl-2H-chromen-4-yl)methanone (21). As described for **14b**, **20** (300 mg, 0.81 mmol) in dry ether (50 ml), MnO₂ (705 mg, 8.10 mmol) furnished **14m** (226 mg, 76%) as colorless semi solid, R_f = 0.71 (AcOEt/hexane, 10:90); ¹H NMR (300 MHz, CDCl₃): δ 7.58 (d, 1H, J = 1.58), 7.44 (dd, 1H, J_1 = 1.7, J_2 = 8.3), 6.80 (d, 1H, J = 8.4), 6.59 (d, 1H, J = 8.4), 6.40 (d, 1H, J = 2.4), 6.27 (dd, 1H,

J_1 = 2.5, J_2 = 8.5), 3.94 (s, 3H), 3.91 (s, 3H), 3.74 (s, 3H), 1.67 (s, 3H), 1.49 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 195.9, 160.3, 153.8, 152.7, 149.3, 131.2, 129.9, 129.5, 125.4, 125.2, 114.5, 110.2, 107.0, 78.4, 55.9, 55.8, 55.0, 25.4, 15.6; MS (ESI): m/z 369 [M + 1]⁺; Anal. Calcd. for C₂₂H₂₄O₅: C, 71.72; H, 6.57. Found: C, 71.63; H, 6.68.

Typical procedure for the aromatic Nazarov cyclization

11-Benzyl-3-methoxy-6,6-dimethyl-6a,11-dihydro-6H,12aH-5-oxa-11-azabenz[5,6]pentaleno[2,1-b]naphthalen-12-one (15b). To a stirred solution of substrate **14b** (200 mg, 0.47 mmol) in anhydrous DCM (20 ml) at room temperature, was added triflic acid (CF₃SO₃H, 0.04 ml, 0.47 mmol) at the same temperature and the solution was stirred vigorously till the completion of reaction. It was then neutralized by saturated Na₂CO₃ solution at 0 °C, extracted with DCM (3 × 10 ml), dried over anhydrous Na₂SO₄. After the evaporation, the residue was subjected to column chromatography on silica gel and elution with 10% ethyl acetate in hexane furnished the cyclized product **15b** (180 mg, 90%) as colorless semi solid, R_f = 0.51 (AcOEt/hexane, 10:90); IR (KBr): 1716, 1217, 1027, 766 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.81 (d, 1H, J = 8.2), 7.73 (dd, 1H, J_1 = 0.5, J_2 = 8.6), 7.42–7.33 (m, 2H), 7.26–7.18 (m, 6H), 6.64 (dd, 1H, J_1 = 2.5, J_2 = 8.5), 6.48 (d, 1H, J = 2.5), 5.62 (d, 1H, J = 15.7), 5.52 (d, 1H, J = 15.6), 4.03 (d, 1H, J = 5.9), 3.91 (d, 1H, J = 5.9), 3.77 (s, 3H), 1.78 (s, 3H), 0.71 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 191.8, 159.6, 153.3, 144.0, 141.8, 138.4, 137.1, 129.9, 128.7, 127.6, 127.1, 126.8, 123.2, 122.5, 120.9, 113.1, 112.0, 107.8, 102.5, 77.9, 55.2, 50.7, 47.5, 43.6, 29.0, 21.7. MS (ESI): m/z 424 [M + 1]⁺, 91 [C₆H₅CH₂]⁺; Anal. Calcd. for C₂₈H₂₅NO₃: C, 79.41; H, 5.95; N, 3.31. Found: C, 79.37; H, 5.88; N, 3.39.

11-Benzyl-3-methoxy-6,6-dimethyl-6a,11-dihydro-6H,12aH-5-thia-11-azabenz[5,6]pentaleno[2,1-b]naphthalen-12-one (15c). As described for **15b**, **14c** (200 mg, 0.45 mmol) in anhydrous DCM (20 ml), triflic acid (0.04 ml, 0.45 mmol) furnished **15c** (184 mg, 92%) as colorless white solid, m.p. 165–170 °C; R_f = 0.53 (AcOEt/hexane, 10:90); IR (KBr): 2926, 2361, 1692, 1594, 1216, 759 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.78 (d, 1H, J = 8.0), 7.63 (d, 1H, J = 9.2), 7.41–7.32 (m, 2H), 7.27–7.17 (m, 6H), 6.82–6.78 (m, 2H), 5.63 (d, 1H, J = 15.8), 5.53 (d, 1H, J = 15.9), 4.19 (d, 1H, J = 5.9), 4.08 (d, 1H, J = 6.0), 3.79 (s, 3H), 1.58 (s, 3H), 1.17 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 191.4, 158.4, 143.9, 141.5, 138.9, 137.1, 134.4, 131.2, 128.6, 127.6, 127.2, 126.6, 125.2, 124.2, 123.1, 120.9, 113.4, 111.9, 111.8, 57.2, 55.2, 49.2, 47.6, 47.5, 26.0; MS (ESI): m/z 440 [M + 1]⁺; Anal. Calcd. for C₂₈H₂₅NO₂S: C, 76.51; H, 5.73; N, 3.19. Found: C, 76.59; H, 5.81; N, 3.11.

11-Benzyl-6,6-dimethyl-6a,11-dihydro-6H,12aH-5-oxa-11-azabenz[5,6]pentaleno[2,1-b]naphthalene (15d). As described for **15b**, **14d** (200 mg, 0.50 mmol) in anhydrous DCM (20 ml), triflic acid (0.045 ml, 0.50 mmol) furnished **15d** (183 mg, 92%) as colorless white solid, m.p. 160–165 °C; R_f = 0.56 (AcOEt/hexane, 10:90); IR (KBr): 2923, 2855, 2361, 1692, 1461, 1217, 759, cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.86–7.80 (m, 2H), 7.42–7.34 (m, 2H), 7.26–7.15 (m, 7H), 7.06–7.01 (m, 1H), 6.90 (dd, 1H, J_1 = 0.9, J_2 = 8.0), 5.63 (d, 1H, J = 15.6), 5.53 (d, 1H, J = 15.7), 4.09 (d, 1H, J = 5.8), 3.93 (d, 1H, J = 6.0), 1.79 (s, 3H), 0.70 (s, 3H);

¹³C NMR (75 MHz, CDCl₃): δ 191.3, 152.4, 144.1, 141.9, 138.3, 137.0, 129.3, 128.7, 127.9, 127.6, 127.1, 126.8, 123.2, 122.5, 121.1, 121.0, 122.0, 77.6, 51.1, 47.5, 43.7, 29.0, 21.6; MS (ESI): *m/z* 394 [M + 1]⁺; Anal. Calcd. for C₂₇H₂₃NO₂: C, 82.42; H, 5.89; N, 3.56. Found: C, 82.38; 5.95; N, 3.63

11-Benzyl-6,6-dimethyl-6a,11-dihydro-6H,12aH-5-thia-11-azabenzof[5,6]pentaleno[2,1-b]naphthalen-12-one (15e). As described for **15b**, **14e** (200 mg, 0.48 mmol) in anhydrous DCM (20 ml), triflic acid (0.04 ml, 0.48 mmol) furnished **15e** (182 mg, 91%) as colorless semi solid, *R_f* = 0.58 (AcOEt/hexane, 10:90); IR (KBr): 3020, 2360, 1691, 1595, 1216, 761, 670 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.80 (d, 1H, *J* = 8.0), 7.71 (d, 1H, *J* = 6.8), 7.42–7.33 (m, 2H), 7.24–7.18 (m, 9H), 5.63 (d, 1H, *J* = 15.6), 5.54 (d, 1H, *J* = 15.6), 4.24 (d, 1H, *J* = 6.0), 4.11 (d, 1H, *J* = 6.0), 1.57 (s, 3H), 1.18 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 190.9, 143.9, 141.6, 139.0, 137.1, 133.4, 133.1, 130.4, 128.7, 128.5, 127.6, 127.2, 127.1, 126.7, 125.5, 124.2, 123.1, 120.9, 111.9, 57.9, 49.4, 47.5, 29.6, 26.0; MS (ESI): *m/z* 410 [M + 1]⁺; Anal. Calcd. for C₂₇H₂₃NOS: C, 79.18; H, 5.66; N, 3.42. Found: C, 79.30; H, 5.75; N, 3.35.

(9-Benzyl-3-methoxy-6,6-dimethyl-6a,9-dihydro-6H,10aH-5-oxa-9-azapentaleno[2,1-a]naphthalen-10-one (15f). As described for **15b**, **14f** (200 mg, 0.53 mmol) in anhydrous DCM (20 ml), triflic acid (0.045 ml, 0.53 mmol) furnished **15f** (170 mg, 85%) as colorless semi solid, *R_f* = 0.49 (AcOEt/hexane, 10:90); IR (KBr): 3020, 2361, 1709, 1216, 1104, 761 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.66 (d, 1H, *J* = 8.6), 7.30–7.21 (m, 5H), 7.01 (d, 1H, *J* = 2.4), 6.58 (dd, 1H, *J*₁ = 2.5, *J*₂ = 8.4), 6.40 (d, 1H, *J* = 2.4), 6.17 (d, 1H, *J* = 2.3), 5.30 (d, 1H, *J* = 14.7), 5.20 (d, 1H, *J* = 14.6), 3.93 (d, 1H, *J* = 6.2), 3.77 (s, 3H), 3.49 (d, 1H, *J* = 6.2 Hz), 1.50 (s, 3H), 1.01 (s, 3H); MS (ESI): *m/z* 374 [M + 1]⁺; Anal. Calcd. for C₂₄H₂₃NO₃: C, 77.19; H, 6.21; N, 3.75. Found: C, 77.26; H, 6.14; N, 3.86.

9-Benzyl-3-methoxy-6,6-dimethyl-6a,9-dihydro-6H,10aH-5-thia-9-azapentaleno[2,1-a]naphthalen-10-one (15g). As described for **15b**, **14g** (200 mg, 0.51 mmol) in anhydrous DCM (20 ml), triflic acid (0.045 ml, 0.51 mmol) furnished **15g** (175 mg, 88%) as colorless semi solid, *R_f* = 0.53 (AcOEt/hexane, 10:90); IR (KBr): 3021, 2360, 1731, 1218, 763, 670 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.80 (d, 1H), 7.33–7.25 (m, 5H), 7.05 (d, 1H, *J* = 2.4), 6.81–6.74 (m, 2H), 6.20 (d, 1H, *J* = 2.4), 5.32 (d, 1H, *J* = 14.8), 5.18 (d, 1H, *J* = 14.7), 4.09 (d, 1H, *J* = 6.7), 3.78 (s, 3H), 3.65 (d, 1H, *J* = 6.3), 1.46 (s, 3H), 1.38 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 187.8, 158.2, 150.3, 137.0, 134.4, 133.9, 133.9, 131.2, 128.8, 127.9, 124.8, 113.5, 111.9, 107.3, 56.8, 55.2, 50.9, 48.7, 46.1, 29.0, 25.9; MS (ESI): *m/z* 390 [M + 1]⁺; Anal. Calcd. for C₂₄H₂₃NO₂S: C, 74.00; H, 5.95; N, 3.60. Found: C, 74.08; H, 6.02; N, 3.53.

9-Benzyl-6,6-dimethyl-6a,9-dihydro-6H,10aH-5-oxa-9-azapentaleno[2,1-a]naphthalen-10-one (15h). As described for **15b**, **14h** (200 mg, 0.58 mmol) in anhydrous DCM (20 ml), triflic acid (0.046 ml, 0.58 mmol) furnished **15h** (174 mg, 87%) as colorless semi solid, *R_f* = 0.45 (AcOEt/hexane, 10:90); IR (KBr): 3021, 2361, 1667, 1595, 1216, 763, 670 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.77 (d, 1H, *J* = 7.6), 7.30–7.21 (m, 5H), 7.16–7.11 (m, 1H), 7.03–6.96 (m, 2H), 6.83 (dd, 1H, *J*₁ = 1.0, *J*₂ = 8.1), 6.18 (d, 1H, *J* = 2.4), 5.31 (d, 1H, *J* = 14.8), 5.21 (d, 1H, *J* =

14.7), 3.99 (d, 1H, *J* = 6.2), 3.52 (d, 1H, *J* = 6.2), 1.51 (s, 3H), 1.00 (s, 3H). MS (ESI): *m/z* 344 [M + 1]⁺; Anal. Calcd. for C₂₃H₂₁NO₂: C, 80.44; H, 6.16; N, 4.08. Found: C, 80.56; H, 6.28; N, 3.98.

3,8,9-Trimethoxy-6,6-dimethyl-6a,11a-dihydro-6H-indeno[1,2-c]chromen-11-one (12a). As described for **15b**, **10a** (200 mg, 0.56 mmol) in anhydrous DCM (20 ml), triflic acid (0.05 ml, 0.56 mmol) furnished **12a** (180 mg, 90%) as colorless semi solid, *R_f* = 0.64 (AcOEt/hexane, 10:90); IR (KBr): 3018, 2925, 2360, 1708, 1591, 1462, 1219, 1035, 762 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+CCl₄): δ 7.65 (d, 1H, *J* = 8.5), 7.24 (s, 1H), 6.98 (s, 1H), 6.61 (dd, 1H, *J*₁ = 2.5, *J*₂ = 8.5), 6.41 (d, 1H, *J* = 2.5), 4.00 (s, 3H), 3.94 (s, 3H), 3.77 (s, 3H), 3.66 (d, 1H, *J* = 5.9), 3.59 (d, 1H, *J* = 5.9), 1.67 (s, 3H), 0.55 (s, 3H); ¹³C NMR (75 MHz, CDCl₃+CCl₄): δ 201.2, 159.6, 154.9, 153.1, 150.2, 147.0, 130.4, 129.8, 112.4, 107.9, 107.8, 105.0, 102.3, 56.2, 56.1, 55.1, 47.3, 46.7, 28.4, 20.6; MS (ESI): *m/z* 355 [M + 1]⁺; Anal. Calcd. for C₂₁H₂₂O₅: C, 71.17; H, 6.26. Found: C, 71.25; H, 6.34.

8,9-Dimethoxy-6,6-dimethyl-6a,11a-dihydro-6H-indeno[1,2-c]chromen-11-one (12b). As described for **15b**, **10b** (200 mg, 0.61 mmol) in anhydrous DCM (20 ml), triflic acid (0.05 ml, 0.61 mmol) furnished **12b** (182 mg, 91%) as colorless semi solid, *R_f* = 0.65 (AcOEt/hexane, 10:90); IR (KBr): 3020, 2360, 1710, 1591, 1219, 1032, 759 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.80 (dd, 1H, *J*₁ = 1.1, *J*₂ = 7.6), 7.28 (s, 1H), 7.21–7.15 (m, 1H), 7.05 (dd, 1H, *J*₁ = 1.1, *J*₂ = 7.4), 7.01 (s, 1H), 6.90–6.87 (m, 1H), 4.01 (s, 3H), 3.94 (s, 3H), 3.72 (d, 1H, *J* = 5.9), 3.67 (d, 1H, *J* = 5.9), 1.70 (s, 3H), 0.56 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 201.0, 154.8, 152.2, 150.0, 147.1, 129.8, 129.5, 127.8, 121.1, 120.2, 117.1, 107.8, 104.9, 77.2, 56.3, 56.1, 47.2, 47.1, 28.3, 20.4; MS (ESI): *m/z* 325 [M + 1]⁺; Anal. Calcd. for C₂₀H₂₀O₄: C, 74.06; H, 6.21. Found: C, 73.95; H, 6.13.

8,9-Dimethoxy-6,6-dimethyl-6a,11a-dihydro-6H-5-thiabenzofluorene-11-one (12c). As described for **15b**, **10c** (200 mg, 0.58 mmol) in anhydrous DCM (20 ml), triflic acid (0.046 ml, 0.58 mmol) furnished **12c** (173 mg, 87%) as colorless semi solid, *R_f* = 0.67 (AcOEt/hexane, 10:90); IR (KBr): 3021, 2360, 1730, 1217, 1044, 764 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+CCl₄): δ 7.75 (d, 1H, *J* = 7.5), 7.25–7.12 (m, 4H), 6.97 (s, 1H), 4.00 (s, 3H), 3.94 (s, 3H), 3.89 (d, 1H, *J* = 5.9), 3.86 (d, 1H, *J* = 5.9), 1.54 (s, 3H), 0.88 (s, 3H); ¹³C NMR (75 MHz, CDCl₃+CCl₄): δ 200.2, 154.4, 150.2, 146.2, 132.7, 131.5, 131.0, 129.8, 127.8, 125.3, 109.0, 104.7, 56.2, 56.0, 53.1, 52.1, 45.7, 28.58, 24.0; MS (ESI): *m/z* 341 [M + 1]⁺; Anal. Calcd. for C₂₀H₂₀O₃S: C, 70.56; H, 5.92. Found: C, 70.44; H, 6.01.

3-Methoxy-6,6-dimethyl-6a,10a-dihydro-6H-5-oxa-7-thiapentaleno[2,1-a]naphthalen-10-one (15i). As described for **15b**, **14i** (200 mg, 0.67 mmol) in anhydrous DCM (20 ml), triflic acid (0.06 ml, 0.67 mmol) furnished **15i** (168 mg, 84%) as colorless semi solid, *R_f* = 0.48 (AcOEt/hexane, 10:90); IR (KBr): 3019, 2360, 1714, 1584, 1215, 760, 669 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.55 (dd, 1H, *J*₁ = 0.6, *J*₂ = 8.5), 7.29 (d, 1H, *J* = 5.0), 7.13 (d, 1H, *J* = 5.2), 6.51 (dd, 1H, *J*₁ = 2.5, *J*₂ = 8.5), 6.30 (d, 1H, *J* = 2.5), 3.93 (d, 1H, *J* = 6.5), 3.71 (d, 1H, *J* = 6.6), 3.68 (s, 3H), 1.51 (s, 3H), 0.91 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 194.5, 166.7, 159.7, 152.9, 146.1, 131.0, 129.8, 120.3, 111.7, 108.3, 102.6, 76.0, 55.1, 51.2, 47.2, 27.2, 22.5; MS (ESI): *m/z* 301 [M + 1]⁺.

Anal. Calcd. for C₁₇H₁₆O₃: S, C, 67.98; H, 5.37. Found: C, 68.07; H, 5.31.

6,6-Dimethyl-6a,11a-dihydro-6H,7H-5,8-dithiacyclopenta[b]-phenanthren-11-one (15j). As described for **15b**, **14j** (200 mg, 0.70 mmol) in anhydrous DCM (20 ml), triflic acid (0.062 ml, 0.70 mmol) furnished **15j** (176 mg, 88%) as colorless semi solid, m.p. 95–100 °C; Yield: 88%, R_f = 0.47 (AcOEt/hexane, 10:90); IR (KBr): 3015, 2351, 1704, 1586, 1219, 760, 669 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.64 (d, 1H, J = 7.5), 7.27 (d, 1H, J = 5.0), 7.17–7.04 (m, 4H), 4.13 (d, 1H, J = 6.6), 3.87 (d, 1H, J = 6.6), 1.44 (s, 3H), 1.24 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 193.2, 167.1, 146.7, 132.1, 131.0, 130.8, 130.3, 128.4, 127.0, 125.7, 120.1, 57.1, 52.3, 44.5, 28.3, 25.4; MS (ESI): m/z 303 [M + NH₄]⁺; Anal. Calcd. for C₁₆H₁₄OS₂: C, 67.10; H, 4.93. Found: C, 67.02; H, 5.01.

6,6-Dimethyl-6a,10a-dihydro-6H-5-oxa-7-thiapentaleno[2,1-a]-naphthalen-10-one (15k). As described for **15b**, **14k** (200 mg, 0.74 mmol) in anhydrous DCM (20 ml), triflic acid (0.065 ml, 0.74 mmol) furnished **15k** (162 mg, 81%) as colorless white solid, m.p. 170–175 °C; R_f = 0.46 (AcOEt/hexane, 10:90); ¹H NMR (300 MHz, CDCl₃): δ 7.78 (d, 1H, J = 7.6), 7.38 (d, 1H, J = 5.7), 7.21 (d, 1H, J = 5.0), 7.17–7.12 (m, 1H), 7.06–6.98 (m, 1H), 6.88 (dd, 1H, J₁ = 1.1, J₂ = 8.0), 4.09 (d, 1H, J = 6.5), 3.83 (d, 1H, J = 6.5), 1.60 (s, 3H), 0.98 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 194.4, 167.1, 152.1, 145.9, 131.3, 129.2, 128.1, 121.5, 120.1, 119.8, 117.5, 75.9, 51.58, 47.23, 27.1, 22.4; MS (ESI): m/z 271 [M + 1]⁺; Anal. Calcd. for C₁₆H₁₄O₂S: C, 71.08; H, 5.22. Found: C, 70.95; H, 5.11.

5-Benzyl-6,6-dimethyl-5,6,6a,10a-tetrahydro-7-thia-5-azapentaleno[2,1-a]naphthalen-10-one (19). As described for **15b**, **18** (200 mg, 0.56 mmol) in anhydrous DCM (20 ml), triflic acid (0.05 ml, 0.56 mmol) furnished **19** (170 mg, 85%) as dark solid, m.p. 100–105 °C; R_f = 0.49 (AcOEt/hexane, 10:90); IR (Neat): 3021, 2360, 1731, 1216, 761, 670 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.69 (d, 1H, J = 7.4), 7.37 (d, 1H, J = 5.1), 7.28–7.16 (m, 6H), 7.02–6.97 (m, 1H), 6.83–6.78 (m, 1H), 6.45 (d, 1H, J = 8.2), 4.59 (d, 1H, J = 17.5), 4.37 (d, 1H, J = 17.5), 4.24 (d, 1H, J = 6.5), 3.82 (d, 1H, J = 6.5), 1.43 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 195.2, 168.2, 146.8, 144.2, 140.2, 131.0, 129.2, 128.5, 127.7, 126.6, 126.0, 120.3, 118.6, 118.1, 114.3, 56.4, 53.8, 51.4, 49.4, 25.0, 24.2; MS (ESI): m/z 360 [M + 1]⁺; Anal. Calcd. for C₂₃H₂₁NOS: C, 76.84; H, 5.89; N, 3.90. Found: C, 76.93; H, 5.97; N, 4.01.

Acknowledgements

This research project was supported by the Department of Science and Technology (SR/S1/OC-23/2005), New Delhi, India in the form of grant. Ritesh and Maloy thank DST and CSIR respectively for fellowships. This has CDRI communication number 7345.

Notes and references

- (a) K. Kawazoe, M. Yamamoto, Y. Takaishi, G. Honda, T. Fujita, E. Sezik and E. Yesilada, *Phytochemistry*, 1999, **50**, 493; (b) W. H. Lin, J. M. Fang and Y. S. Cheng, *Phytochemistry*, 1995, **40**, 871; (c) H. Ohtsu, M. Iwamoto, H. Ohishi, S. Matsunaga and R. Tanaka, *Tetrahedron Lett.*, 1999, **40**, 6419.
- (a) W. H. Lin, J. M. Fang and Y. S. Cheng, *Phytochemistry*, 1996, **42**, 1657; (b) C. I. Chang, S. C. Chien, S. M. Lee and Y. H. Kuo, *Chem. Pharm. Bull.*, 2003, **51**, 1420.
- C. I. Chang, J. Y. Chang, C. C. Kuo, W. Y. Pan and W. Y. Kuo, *Planta Med.*, 2005, **71**, 72.
- (a) M. Iwamoto, H. Ohtsu, H. Tokuda, H. Nishino, S. Matsunaga and R. Tanaka, *Bioorg. Med. Chem.*, 2001, **9**, 1911; (b) T. Minami, M. Wamoto, H. Ohtsu, H. Ohishi, R. Tanaka and A. Yoshitake, *Planta Med.*, 2002, **68**, 742.
- (a) E. Fillion and D. Fishlock, *J. Am. Chem. Soc.*, 2005, **127**, 13144; (b) R. M. McFadden and B. M. Stoltz, *J. Am. Chem. Soc.*, 2006, **128**, 7738; (c) M. Banerjee, R. Mukhopadhyay, B. Achari and A. K. Banerjee, *Org. Lett.*, 2003, **5**, 3931; (d) L. Planas, M. Mogi, H. Takita, T. Kajimoto and M. Node, *J. Org. Chem.*, 2006, **71**, 2896; (e) M. Banerjee, R. Mukhopadhyay, B. Achari and A. K. Banerjee, *J. Org. Chem.*, 2006, **71**, 2787.
- For recent reviews on Nazarov chemistry, see: (a) M. Harmata, *Chemtracts*, 2004, **17**, 416; (b) M. A. Tius, *Eur. J. Org. Chem.*, 2005, **11**, 2193; (c) A. J. Frontier and C. Collison, *Tetrahedron*, 2005, **61**, 7577; (d) H. Pellissier, *Tetrahedron*, 2005, **61**, 6479.
- (a) V. Aggarwal and A. Belfield, *Org. Lett.*, 2003, **5**, 5075; (b) E. Occhiato, C. Prandi, A. Ferrali, A. Guarna and P. Venturello, *J. Org. Chem.*, 2003, **68**, 9728; (c) C. Bee, E. Leclerc and M. A. Tius, *Org. Lett.*, 2003, **5**, 4927; (d) D. Trauner, S. Gradl and G. Liang, *Org. Lett.*, 2003, **5**, 4913.
- (a) S. E. Denmark, M. A. Wallace and C. B. Walker, *J. Org. Chem.*, 1990, **55**, 5543; (b) S. E. Denmark and R. C. Klix, *Tetrahedron*, 1988, **44**, 4043; (c) J. A. Bender, A. M. Arif and F. G. West, *J. Am. Chem. Soc.*, 1999, **121**, 7443; (d) C. C. Browder, F. P. Marmsater and F. G. West, *Org. Lett.*, 2001, **3**, 3033.
- G. Liang, Y. Xu, I. B. Seiple and D. Trauner, *J. Am. Chem. Soc.*, 2006, **128**, 11022.
- (a) G. Mehta and N. Krishnamurthy, *J. Chem. Soc., Chem. Commun.*, 1986, 1319; (b) S. E. Denmark, K. L. Habermas and G. A. Hite, *Helv. Chim. Acta*, 1988, **71**, 168; (c) S. E. Denmark, M. A. Wallace, Jr. and C. B. Walker, *J. Org. Chem.*, 1990, **55**, 5543; (d) C. Prandi, A. Ferrali, A. Guarna, P. Venturello and E. G. Occhiato, *J. Org. Chem.*, 2004, **69**, 7705.
- R. D. Mazzola, Jr., T. D. White, H. R. Vollmer-Snarr and F. G. West, *Org. Lett.*, 2005, **7**, 2799.
- (a) K. F. Cheng, K. P. Chan and T. F. Lai, *J. Chem. Soc., Perkin Trans. 1*, 1991, 2461; (b) C. Song, D. Knight and M. Whatton, *Org. Lett.*, 2006, **8**, 163; (c) J. A. Malona, J. M. Colbourne and A. J. Frontier, *Org. Lett.*, 2006, **8**, 5661.
- (a) Shagufra, M. K. Parai and G. Panda, *Tetrahedron Lett.*, 2005, **46**, 8849; (b) Shagufra, A. K. Srivastava and G. Panda, *Tetrahedron Lett.*, 2006, **47**, 1065; (c) M. K. Parai, Shagufra, A. K. Srivastava, M. Kassack and G. Panda, *Tetrahedron*, 2008, **64**, 9962; (d) Shagufra, R. Raghunandan, P. R. Moulik and G. Panda, *Tetrahedron Lett.*, 2005, **46**, 5337; (e) C. D. Gabbutt, D. J. Hartley, J. D. Hepworth, B. M. Heron, M. Kanjia and M. M. Rahman, *Tetrahedron*, 1994, **50**, 2507; (f) C. D. Gabbutt, J. D. Hepworth and B. M. Heron, *J. Chem. Soc., Perkin Trans. 1*, 1994, 653.
- R. K. Akuamoah, P. E. Brown, W. Y. Marcus and J. E. Steele, *J. Chem. Soc., Perkin Trans. 1*, 1995, 197.
- (a) M. A. Weaver, D. J. Wallace, and J. M. Straley, *U. S. Patent* 3 247, 211, 1996; (b) M. A. Marsini, K. M. Gowin and T. R. R. Pettus, *Org. Lett.*, 2006, **8**, 3481.
- I. Fleming, *Frontier Orbitals and Organic Chemical Reactions*, John Wiley & Sons, Ltd., New York, NY, 1976, Chapter 3, p. 57.